GEO-CM04S1 vs mRNA SARS-COV-2 Vaccine
A Phase 2 Randomized, Multi-center Study of GEO-CMO4S1 (SARS-CoV-2 Vaccine) Versus mRNA SARS-CoV-2 Vaccine in Patients Post Cellular Therapy for Hematological Malignancies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 240 patients (estimated)
- Sponsors
- GeoVax, Inc.
- Tags
- Vaccine, COVID-19 Trials, Randomization
- Trial Type
- Supportive
- Last Update
- 2 weeks ago
- SparkCures ID
- 1889
- NCT Identifier
- NCT04977024
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.